Piper Jaffray analyst Matt O'Brien raised his price target for OrthoPediatrics to $43 from $35 and reiterates an Overweight rating on the name after hosting investor meetings with management. The tone from management "remains quite bullish," O'Brien tells investors in a research note. He expects to continue seeing "some of the best top-line growth" in all of orthopedics from the name in the coming years. New set deployment continues to drive much of the revenue growth, and this dynamic should last for years, says O'Brien. He "strongly" encourages investors buy OrthoPediatrics shares at current levels.